Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.

The public health response

Vincent P. Hsu, Susan L. Lukacs, Thomas Handzel, James Hayslett, Scott Harpe, Thomas Hales, Vera A. Semenova, Sandra Romero-Steiner, Cheryl Elie, Conrad P. Quinn, Rima Khabbaz, Ali S Khan, Gregory Martin, John Eisold, Anne Schuchat, Rana A. Hajjeh

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

On October 15, 2001, a U.S. Senate staff member opened an envelope containing Bacillus anthracis spores. Chemoprophylaxis was promptly initiated and nasal swabs obtained for all persons in the immediate area. An epidemiologic investigation was conducted to define exposure areas and identify persons who should receive prolonged chemoprophylaxis, based on their exposure risk. Persons immediately exposed to B. anthracis spores were interviewed; records were reviewed to identify additional persons in this area. Persons with positive nasal swabs had repeat swabs and serial serologic evaluation to measure antibodies to B. anthracis protective antigen (anti-PA). A total of 625 persons were identified as requiring prolonged chemoprophylaxis; 28 had positive nasal swabs. Repeat nasal swabs were negative at 7 days; none had developed anti-PA antibodies by 42 days after exposure. Early nasal swab testing is a useful epidemiologic tool to assess risk of exposure to aerosolized B. anthracis. Early, wide chemoprophylaxis may have averted an outbreak of anthrax in this population.

Original languageEnglish (US)
Pages (from-to)1039-1043
Number of pages5
JournalEmerging infectious diseases
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

Bacillus anthracis
Nose
Public Health
Chemoprevention
Spores
Anthrax
Antibodies
Disease Outbreaks
Antigens
Population

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Hsu, V. P., Lukacs, S. L., Handzel, T., Hayslett, J., Harpe, S., Hales, T., ... Hajjeh, R. A. (2002). Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C. The public health response. Emerging infectious diseases, 8(10), 1039-1043. https://doi.org/10.3201/eid0810.020332

Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C. The public health response. / Hsu, Vincent P.; Lukacs, Susan L.; Handzel, Thomas; Hayslett, James; Harpe, Scott; Hales, Thomas; Semenova, Vera A.; Romero-Steiner, Sandra; Elie, Cheryl; Quinn, Conrad P.; Khabbaz, Rima; Khan, Ali S; Martin, Gregory; Eisold, John; Schuchat, Anne; Hajjeh, Rana A.

In: Emerging infectious diseases, Vol. 8, No. 10, 01.10.2002, p. 1039-1043.

Research output: Contribution to journalArticle

Hsu, VP, Lukacs, SL, Handzel, T, Hayslett, J, Harpe, S, Hales, T, Semenova, VA, Romero-Steiner, S, Elie, C, Quinn, CP, Khabbaz, R, Khan, AS, Martin, G, Eisold, J, Schuchat, A & Hajjeh, RA 2002, 'Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C. The public health response', Emerging infectious diseases, vol. 8, no. 10, pp. 1039-1043. https://doi.org/10.3201/eid0810.020332
Hsu, Vincent P. ; Lukacs, Susan L. ; Handzel, Thomas ; Hayslett, James ; Harpe, Scott ; Hales, Thomas ; Semenova, Vera A. ; Romero-Steiner, Sandra ; Elie, Cheryl ; Quinn, Conrad P. ; Khabbaz, Rima ; Khan, Ali S ; Martin, Gregory ; Eisold, John ; Schuchat, Anne ; Hajjeh, Rana A. / Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C. The public health response. In: Emerging infectious diseases. 2002 ; Vol. 8, No. 10. pp. 1039-1043.
@article{e35baeced5fa4525a1e9e5425e2b1b6c,
title = "Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: The public health response",
abstract = "On October 15, 2001, a U.S. Senate staff member opened an envelope containing Bacillus anthracis spores. Chemoprophylaxis was promptly initiated and nasal swabs obtained for all persons in the immediate area. An epidemiologic investigation was conducted to define exposure areas and identify persons who should receive prolonged chemoprophylaxis, based on their exposure risk. Persons immediately exposed to B. anthracis spores were interviewed; records were reviewed to identify additional persons in this area. Persons with positive nasal swabs had repeat swabs and serial serologic evaluation to measure antibodies to B. anthracis protective antigen (anti-PA). A total of 625 persons were identified as requiring prolonged chemoprophylaxis; 28 had positive nasal swabs. Repeat nasal swabs were negative at 7 days; none had developed anti-PA antibodies by 42 days after exposure. Early nasal swab testing is a useful epidemiologic tool to assess risk of exposure to aerosolized B. anthracis. Early, wide chemoprophylaxis may have averted an outbreak of anthrax in this population.",
author = "Hsu, {Vincent P.} and Lukacs, {Susan L.} and Thomas Handzel and James Hayslett and Scott Harpe and Thomas Hales and Semenova, {Vera A.} and Sandra Romero-Steiner and Cheryl Elie and Quinn, {Conrad P.} and Rima Khabbaz and Khan, {Ali S} and Gregory Martin and John Eisold and Anne Schuchat and Hajjeh, {Rana A.}",
year = "2002",
month = "10",
day = "1",
doi = "10.3201/eid0810.020332",
language = "English (US)",
volume = "8",
pages = "1039--1043",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "10",

}

TY - JOUR

T1 - Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.

T2 - The public health response

AU - Hsu, Vincent P.

AU - Lukacs, Susan L.

AU - Handzel, Thomas

AU - Hayslett, James

AU - Harpe, Scott

AU - Hales, Thomas

AU - Semenova, Vera A.

AU - Romero-Steiner, Sandra

AU - Elie, Cheryl

AU - Quinn, Conrad P.

AU - Khabbaz, Rima

AU - Khan, Ali S

AU - Martin, Gregory

AU - Eisold, John

AU - Schuchat, Anne

AU - Hajjeh, Rana A.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - On October 15, 2001, a U.S. Senate staff member opened an envelope containing Bacillus anthracis spores. Chemoprophylaxis was promptly initiated and nasal swabs obtained for all persons in the immediate area. An epidemiologic investigation was conducted to define exposure areas and identify persons who should receive prolonged chemoprophylaxis, based on their exposure risk. Persons immediately exposed to B. anthracis spores were interviewed; records were reviewed to identify additional persons in this area. Persons with positive nasal swabs had repeat swabs and serial serologic evaluation to measure antibodies to B. anthracis protective antigen (anti-PA). A total of 625 persons were identified as requiring prolonged chemoprophylaxis; 28 had positive nasal swabs. Repeat nasal swabs were negative at 7 days; none had developed anti-PA antibodies by 42 days after exposure. Early nasal swab testing is a useful epidemiologic tool to assess risk of exposure to aerosolized B. anthracis. Early, wide chemoprophylaxis may have averted an outbreak of anthrax in this population.

AB - On October 15, 2001, a U.S. Senate staff member opened an envelope containing Bacillus anthracis spores. Chemoprophylaxis was promptly initiated and nasal swabs obtained for all persons in the immediate area. An epidemiologic investigation was conducted to define exposure areas and identify persons who should receive prolonged chemoprophylaxis, based on their exposure risk. Persons immediately exposed to B. anthracis spores were interviewed; records were reviewed to identify additional persons in this area. Persons with positive nasal swabs had repeat swabs and serial serologic evaluation to measure antibodies to B. anthracis protective antigen (anti-PA). A total of 625 persons were identified as requiring prolonged chemoprophylaxis; 28 had positive nasal swabs. Repeat nasal swabs were negative at 7 days; none had developed anti-PA antibodies by 42 days after exposure. Early nasal swab testing is a useful epidemiologic tool to assess risk of exposure to aerosolized B. anthracis. Early, wide chemoprophylaxis may have averted an outbreak of anthrax in this population.

UR - http://www.scopus.com/inward/record.url?scp=0036774151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036774151&partnerID=8YFLogxK

U2 - 10.3201/eid0810.020332

DO - 10.3201/eid0810.020332

M3 - Article

VL - 8

SP - 1039

EP - 1043

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 10

ER -